Retatrutide is a once-weekly triple agonist (GLP-1, GIP, glucagon) dosed by titration: start at 2 mg/week and increase by 2 mg every 4 weeks up to a maintenance dose of 8–12 mg/week. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL), a 2 mg dose draws 40 units on a 1 mL insulin syringe.
Quick math: mg ÷ mL = concentration. Weekly mg ÷ concentration = mL per injection. mL × 100 = insulin units.
Pre-configured for Retatrutide. Weekly dosing with built-in titration schedule.
Retatrutide (LY-3437943) is a synthetic peptide developed as a triple receptor agonist — it simultaneously activates GLP-1, GIP, and glucagon receptors. This three-receptor activation differentiates it from the two-receptor mechanism of Tirzepatide (GLP-1 + GIP) and the single-receptor mechanism of Semaglutide (GLP-1 only).
In Phase 2 clinical research it produced the largest weight reductions of any incretin-class peptide reported to date — around 24% mean body weight reduction at 48 weeks at the 12 mg/week dose, with no observed plateau through the trial duration.
Retatrutide is titrated — meaning the dose is increased gradually over several months rather than starting at the target dose. The standard titration schedule starts at 2 mg/week and increases by 2 mg every 4 weeks until reaching a maintenance dose between 8 and 12 mg/week.
Retatrutide ships as a lyophilized (freeze-dried) white powder. You mix it with bacteriostatic water (0.9% benzyl alcohol) before use. Because Retatrutide doses are in milligrams (not micrograms like most research peptides), draw volumes are larger — typically 0.2–1.2 mL per injection.
Use a fresh 70% isopropyl prep pad on the rubber septum of both the Retatrutide vial and the bacteriostatic water vial. Air-dry 10 seconds.
Use a 3 mL syringe with a drawing needle to pull the calculated volume. 2 mL per 10 mg vial is the most popular ratio (5 mg/mL concentration).
Angle the needle so water trickles down the glass — not directly onto the powder. Direct stream causes foaming.
Roll the vial between your palms for 20–30 seconds until fully dissolved. Shaking creates foam that degrades the peptide.
It should be completely clear and colorless. Any cloudiness, particles, or yellow tint means the peptide is degraded or contaminated — discard.
Write the reconstitution date and concentration on the vial. Store at 2–8°C (36–46°F). Use within 30 days.
Because Retatrutide doses span a wide range (2 to 12 mg) and draw volumes are already larger than typical peptides, picking the right reconstitution ratio matters:
| Vial | BAC water | Concentration | 2 mg dose = | 8 mg dose = | 12 mg dose = |
|---|---|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 20 units | 80 units | too large |
| 10 mg | 2 mL | 5 mg/mL | 40 units | too large | too large |
| 15 mg | 3 mL | 5 mg/mL | 40 units | too large | too large |
| 20 mg | 2 mL | 10 mg/mL | 20 units | 80 units | too large |
| 20 mg | 4 mL | 5 mg/mL | 40 units | too large | too large |
| 30 mg | 3 mL | 10 mg/mL | 20 units | 80 units | too large |
10 mg / 2 mL mix (5 mg/mL) is the most popular for early titration (2–4 mg/week). At higher maintenance doses (8–12 mg/week), a more concentrated 10 mg/mL mix keeps draws within a single insulin syringe.
High maintenance doses (10–12 mg/week) can exceed a single 1 mL syringe at common concentrations. Two practical workarounds:
Retatrutide's side effect profile is similar to other incretin peptides but more pronounced due to the triple receptor activation. The vast majority are gastrointestinal and dose-dependent:
| Side effect | Frequency in Phase 2 | Typical management |
|---|---|---|
| Nausea | ~40–60% | Slow titration, ginger, smaller meals |
| Vomiting | ~25–35% | Hold dose, do not titrate up that month |
| Diarrhea | ~20–30% | Hydration, BRAT diet, hold dose if severe |
| Constipation | ~15–25% | Fiber, hydration, stool softener |
| Injection site reaction | ~5–10% | Rotate injection sites weekly |
| Heart rate increase | ~5–10 bpm | Monitor, usually transient |
Keep in the original vial or one with similar amber/opaque packaging. Don't leave the vial at room temperature for extended periods — pull from the fridge, draw your dose, return immediately.
The maximum dose studied in Phase 2 was 12 mg once weekly. Doses above this haven't been tested in published clinical research. Maintenance doses of 8 mg or 10 mg are commonly used by people who don't tolerate 12 mg.
Appetite suppression is typically noticeable within 1–2 weeks. Measurable weight loss appears around weeks 4–6. Because Retatrutide is titrated up over 12–16 weeks, the most significant weight reduction usually starts after reaching the 6–8 mg/week dose level.
Strongly not recommended. The +2 mg per 4 weeks titration exists specifically because Phase 2 trial participants who titrated faster experienced severe nausea, vomiting, and dropout rates above 30%. The slow ramp gives the GI tract time to adapt to triple receptor activation.
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Tirzepatide is a dual agonist (GLP-1 + GIP only). The glucagon receptor activation in Retatrutide adds direct energy expenditure increase on top of the appetite suppression both share. In Phase 2 head-to-head equivalents, Retatrutide produced approximately 24% body weight reduction at 48 weeks vs ~21% for Tirzepatide.
Any day, but pick one and stick with it. The 6-day half-life means dosing on the same day each week produces stable, predictable blood levels. Many people pick Sunday so any peak side effects fall on a weekend. Once chosen, only shift the day if you're more than 48 hours late — otherwise inject as soon as you remember and continue the original schedule.
Stacking with other peptides is generally avoided during Retatrutide titration because it makes side effect attribution difficult. Once on a stable maintenance dose, some users add BPC-157 for tissue healing or short cycles of growth-hormone-releasing peptides. Do not combine with other GLP-1, GIP, or glucagon agonists.
If the missed dose is within 48 hours of the scheduled day, inject as soon as you remember and continue your normal schedule. If more than 48 hours late, skip the missed dose and resume on the next scheduled day — never double up to "catch up." Doubling a Retatrutide dose causes severe GI side effects.